Product
BMS-986016
4 clinical trials
5 indications
Indication
Colorectal CancerIndication
Colon CancerIndication
Hematologic NeoplasmsIndication
GlioblastomaClinical trial
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon CancerStatus: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (Relatlimab, BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell MalignanciesStatus: Completed, Estimated PCD: 2022-02-16
Clinical trial
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Cytokine Microdialysis For Real Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeStatus: Completed, Estimated PCD: 2023-04-21